You can use your existing Medical Independent, MediLearning or PharmacistCPD account to log in.


Medicalindependent.ie is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.


The benefits of registering: only registered users:
  • receive the ecCopy two days prior to the printed edition.
  • have automatic access to our free CPD sites.
  • can partake in our online MCQs.
  • can enter our online sports quiz.

Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

Download the new Mindo app for both IOS & Android.

  • Get notified when a story goes live
  • Access Premium Content
  • Read Offline
 

You are reading 1 of 2 free-access articles allowed for 30 days

NCCP chief urges HSE to make arrangements for patients requiring CAR-T cell therapy

By Mindo - 19th Sep 2019 | 5 views

The Director of the National Cancer Control Programme (NCCP) recently made an appeal to senior HSE management to fund and arrange treatment for patients requiring chimeric antigen receptor (CAR) T-cell therapy, the Medical Independent (MI) can report.

In an email to HSE General Manager Ms Catherine Donohoe, on 20 June 2019, seen by MI through Freedom of Information law, Dr Jerome Coffey noted that three applications to access the treatment had been submitted to the treatment abroad scheme.

The three applications comprised two paediatric leukaemia patients and one adult lymphoma patient.

Dr Coffey wrote that all have been assessed, “to varying degrees”, by Great Ormond Street Hospital in London, and University College London Hospitals NHS Foundation Trust and were deemed appropriate for treatment.

“Notwithstanding the ongoing appraisal process, the cost of this treatment option and all other related issues I feel that this is the clinically appropriate option for these patients and I would be grateful if you would assist with the necessary arrangements for the patients and their families,” stated Dr Coffey.

The CEO’s Office, the Chief Finance Officer, the Chief Operations Officer, and Director of Acute Operations were also cc’d in the mail.

Chimeric Antigen Receptor (CAR) T-cell therapy involves genetic modification of patients’ autologous T-cells to express a CAR specific for a tumour antigen, following by ex vivo cell expansion and re-infusion back to the patient.

This T-cell genetic modification may occur either via viral-based gene transfer methods or nonviral methods, such as DNA-based transposons, CRISPR/Cas9 technology or direct transfer of in vitro transcribed-mRNA by electroporation.

A spokesperson for the HSE told MI that the patients in question were approved to travel abroad for treatment.

The spokesperson added that further applications for the treatment have also been made.

When asked about the appraisals process, the spokesperson stated: “CAR-T cell therapy is a drug and is being assessed under the HSE reimbursement process. The duration of the assessment varies.”

Currently two Irish hospitals are preparing to provide CAT-T cell therapy – St James’s Hospital, Dublin, and Children’s Health Ireland, Crumlin.

Leave a Reply

Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read